| 1.866 0.056 (3.09%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.4 | 1-year : | 4.41 |
| Resists | First : | 2.91 | Second : | 3.77 |
| Pivot price | 1.97  |
|||
| Supports | First : | 1.51 | Second : | 1.26 |
| MAs | MA(5) : | 1.89 |
MA(20) : | 2.06 |
| MA(100) : | 3.7 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 25.2 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 41.2 | Low : | 1.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HCWB ] has closed above bottom band by 22.2%. Bollinger Bands are 76.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.74 - 1.76 | 1.76 - 1.77 |
| Close: | 1.85 - 1.87 | 1.87 - 1.88 |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Wed, 19 Nov 2025
HCW Biologics (NASDAQ: HCWB) Announces $4M Warrant Deal, 3,020,410 New Warrants - Stock Titan
Tue, 18 Nov 2025
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewswire
Fri, 14 Nov 2025
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
Wed, 22 Oct 2025
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Tue, 16 Sep 2025
Breakthrough Cancer Drug Outperforms Keytruda: HCW Biologics' HCW11-040 Shows Promise Without Cytokine Storm - Stock Titan
Tue, 09 Sep 2025
100% Survival Rate: HCW Biologics' Novel T-Cell Therapy Shows Promise for Hard-to-Treat Pancreatic Cancer - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.85e+006 (%) |
| Held by Institutions | 21.7 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.16e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 95.2 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | 422030 % |
| Gross Profit (p.s.) | -143.74 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 125985 |
| Qtrly Earnings Growth | -13.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.57 |
| Dividend | 0 |
| Forward Dividend | 11240 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|